Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

17. Referanser

Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., . . . Team, N. L. S. T. R. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873

Aberle, D. R., DeMello, S., Berg, C. D., Black, W. C., Brewer, B., Church, T. R., . . . Team, N. L. S. T. R. (2013). Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med, 369(10), 920-931. https://doi.org/10.1056/NEJMoa1208962

Ackman, J. B., & Wu, C. C. (2011). MRI of the thymus. AJR Am J Roentgenol, 197(1), W15-20. https://doi.org/10.2214/AJR.10.4703

Adabag, A. S., Wassif, H. S., Rice, K., Mithani, S., Johnson, D., Bonawitz-Conlin, J., . . . Kelly, R. F. (2010). Preoperative pulmonary function and mortality after cardiac surgery. Am Heart J, 159(4), 691-697. https://doi.org/10.1016/j.ahj.2009.12.039

Adams, R. F., Gray, W., Davies, R. J., & Gleeson, F. V. (2001). Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 120(6), 1798-1802.

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., . . . Investigators, C. (2020). Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med, 382(17), 1599-1607. https://doi.org/10.1056/NEJMoa1915103

Aguilar, E., Gainor, J., Kravets, S., Khosrowjerdi, S., Lydon, C., Adeni, A., . . . Awad, M. (2018). Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 0-89% vs 90-100%. J Thorac Oncol, 13(10), S367-S368.

Al-Sahaf, M., & Lim, E. (2015). The association between surgical volume, survival and quality of care. J Thorac Dis, 7(Suppl 2), S152-155. https://doi.org/10.3978/j.issn.2072-1439.2015.04.08

Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., . . . Cox, J. D. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374(9687), 379-386. https://doi.org/10.1016/S0140-6736(09)60737-6

Alberts, W. M., & Physicians, A. C. o. C. (2007). Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest, 132(3 Suppl), 1S-19S. https://doi.org/10.1378/chest.07-1860

Ambrosini, V., Nicolini, S., Caroli, P., Nanni, C., Massaro, A., Marzola, M. C., . . . Fanti, S. (2012). PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol, 81(5), 988-1001. https://doi.org/10.1016/j.ejrad.2011.03.020

Anderson, G., & Takahama, Y. (2012). Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol, 33(6), 256-263. https://doi.org/10.1016/j.it.2012.03.005

Anderson, K. L., Mulvihill, M. S., Speicher, P. J., Yerokun, B. A., Gulack, B. C., Nussbaum, D. P., . . . Hartwig, M. G. (2017). Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg, 104(4), 1221-1230. https://doi.org/10.1016/j.athoracsur.2017.05.011

Ando, K., Akimoto, K., Sato, H., Manabe, R., Kishino, Y., Homma, T., . . . Sagara, H. (2020). Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers (Basel), 12(4). https://doi.org/10.3390/cancers12040942

Annema, J. T., van Meerbeeck, J. P., Rintoul, R. C., Dooms, C., Deschepper, E., Dekkers, O. M., . . . Tournoy, K. G. (2010). Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA, 304(20), 2245-2252. https://doi.org/10.1001/jama.2010.1705

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . Investigators, P. (2018). Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 379(24), 2342-2350. https://doi.org/10.1056/NEJMoa1809697

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . Investigators, P. (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 377(20), 1919-1929. https://doi.org/10.1056/NEJMoa1709937

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., . . . Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol, 36(28), 2872-2878. https://doi.org/10.1200/JCO.2018.79.0006

Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., . . . Preiser, J. C. (2017). ESPEN guidelines on nutrition in cancer patients. Clin Nutr, 36(1), 11-48. https://doi.org/10.1016/j.clnu.2016.07.015

Arrieta, O., Cardona, A. F., Lara-Mejía, L., Heredia, D., Barrón, F., Zatarain-Barrón, Z. L., . . . Rosell, R. (2020). Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Crit Rev Oncol Hematol, 153, 103033. https://doi.org/10.1016/j.critrevonc.2020.103033

Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V. W., Vansteenkiste, J. F., . . . International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, A. v. B. M., and Participating Institutions. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 10(12), 1675-1684. https://doi.org/10.1097/JTO.0000000000000678

Ashraf, H., Dirksen, A., Loft, A., Bertelsen, A. K., Bach, K. S., Hansen, H., . . . Mortensen, J. (2011). Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax, 66(4), 315-319. https://doi.org/10.1136/thx.2010.136747

Auperin, A., Arriagada, R., Pignon, J. P., Le Pechoux, C., Gregor, A., Stephens, R. J., . . . Aisner, J. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 341(7), 476-484.

Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., . . . Pignon, J. P. (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 28(13), 2181-2190. https://doi.org/10.1200/JCO.2009.26.2543

Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., . . . Sholl, L. M. (2016). MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. https://doi.org/10.1200/JCO.2015.63.4600

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., . . . Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27(36), 6251-6266.

Baize, N., Monnet, I., Greillier, L., Geier, M., Lena, H., Janicot, H., . . . investigators, G. F. d. P.-C. (2020). Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol, 21(9), 1224-1233. https://doi.org/10.1016/S1470-2045(20)30461-7

Bankier, A. A., MacMahon, H., Goo, J. M., Rubin, G. D., Schaefer-Prokop, C. M., & Naidich, D. P. (2017). Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology, 285(2), 584-600. https://doi.org/10.1148/radiol.2017162894

Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., . . . Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30673-9

Bastarrika, G., García-Velloso, M. J., Lozano, M. D., Montes, U., Torre, W., Spiteri, N., . . . Zulueta, J. J. (2005). Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med, 171(12), 1378-1383. https://doi.org/10.1164/rccm.200411-1479OC

Baumann, P., Nyman, J., Hoyer, M., Gagliardi, G., Lax, I., Wennberg, B., . . . Lewensohn, R. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol, 88(3), 359-367. https://doi.org/10.1016/j.radonc.2008.07.019

Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., . . . Lewensohn, R. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol, 27(20), 3290-3296.

Benna, M., Guy, J. B., Bosacki, C., Jmour, O., Ben Mrad, M., Ogorodniitchouk, O., . . . Vallard, A. (2020). Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? Br J Radiol, 93(1109), 20190147. https://doi.org/10.1259/bjr.20190147

Berardi, R., De Lisa, M., Pagliaretta, S., Onofri, A., Morgese, F., Savini, A., . . . Cascinu, S. (2014). Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev, 40(4), 495-506. https://doi.org/10.1016/j.ctrv.2013.11.003

Berry, M. F., D'Amico, T. A., Onaitis, M. W., & Kelsey, C. R. (2014). Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Ann Thorac Surg, 98(1), 197-202. https://doi.org/10.1016/j.athoracsur.2014.03.018

Bhattacharya, S., Bairagya, T. D., Das, A., Mandal, A., & Das, S. K. (2012). Closed pleural biopsy is still useful in the evaluation of malignant pleural effusion. J Lab Physicians, 4(1), 35-38. https://doi.org/10.4103/0974-2727.98669

Bi, N., & Wang, L. (2015). Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. Semin Radiat Oncol, 25(2), 122-132. https://doi.org/10.1016/j.semradonc.2014.11.003

Bischof, M., Debus, J., Herfarth, K., Muley, T., Kappes, J., Storz, K., & Hoffmann, H. (2007). Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther Onkol, 183(12), 679-684.

Bissett, D., Macbeth, F. R., & Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol), 3(6), 315-317.

Blackhall, F. H., Peters, S., Bubendorf, L., Dafni, U., Kerr, K. M., Hager, H., . . . Stahel, R. A. (2014). Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol, 32(25), 2780-2787. https://doi.org/10.1200/JCO.2013.54.5921

Bolliger, C. T., Sutedja, T. G., Strausz, J., & Freitag, L. (2006). Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. Eur Respir J, 27(6), 1258-1271.

Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., . . . Gandhi, L. (2019). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol, 14(1), 124-129. https://doi.org/10.1016/j.jtho.2018.08.004

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., . . . Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373(17), 1627-1639. https://doi.org/10.1056/NEJMoa1507643

Boyar Cetinkaya, R., Aagnes, B., Thiis-Evensen, E., Tretli, S., Bergestuen, D. S., & Hansen, S. (2017). Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology, 104(1), 1-10. https://doi.org/10.1159/000442207

Bradbury, P., Sivajohanathan, D., Chan, A., Kulkarni, S., Ung, Y., & Ellis, P. M. (2016). Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2016.07.002

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., . . . Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373(2), 123-135. https://doi.org/10.1056/NEJMoa1504627

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., . . . Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer, 9(6). https://doi.org/10.1136/jitc-2021-002435

Brcic, L., & Kern, I. (2020). Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl Lung Cancer Res, 9(3), 924-933. https://doi.org/10.21037/tlcr.2020.03.38

Brock, M. V., Hooker, C. M., Syphard, J. E., Westra, W., Xu, L., Alberg, A. J., . . . Yang, S. C. (2005). Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg, 129(1), 64-72. https://doi.org/10.1016/j.jtcvs.2004.08.022

Brokx, H. A. P., Risse, E. K., Paul, M. A., Grunberg, K., Golding, R. P., Kunst, P. W. A., . . . Sutedja, T. G. (2007). Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg, 133(4), 973-978.

Brown, D. J. (2006). Palliation of breathlessness. Clin Med (Lond), 6(2), 133-136. https://doi.org/10.7861/clinmedicine.6-2-133

Brown, P. D., Ballman, K. V., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Whitton, A. C., . . . Roberge, D. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 18(8), 1049-1060. https://doi.org/10.1016/S1470-2045(17)30441-2

Brunelli, A., Belardinelli, R., Pompili, C., Xiumé, F., Refai, M., Salati, M., & Sabbatini, A. (2012). Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection. Ann Thorac Surg, 93(6), 1802-1806. https://doi.org/10.1016/j.athoracsur.2012.03.022

Brunelli, A., Charloux, A., Bolliger, C. T., Rocco, G., Sculier, J. P., Varela, G., . . . therapy, E. R. S. a. E. S. o. T. S. j. t. f. o. f. f. r. (2009). ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J, 34(1), 17-41. https://doi.org/10.1183/09031936.00184308

Brunelli, A., Pompili, C., & Salati, M. (2010). Low-technology exercise test in the preoperative evaluation of lung resection candidates. Monaldi Arch Chest Dis, 73(2), 72-78.

Brustugun, O. T., Grønberg, B. H., Fjellbirkeland, L., Helbekkmo, N., Aanerud, M., Grimsrud, T. K., . . . Solberg, S. K. (2018). Substantial nation-wide improvement in lung cancer relative survival in  Norway from 2000 to 2016   Lung Cancer, 122, 138-145.

Brustugun, O. T., Helland, Å., Fjellbirkeland, L., Kleinberg, L., Ariansen, S., Jebsen, P., . . . Helgeland, L. (2012). Mutasjonstesting ved ikke-småcellet lungekreft. Tidsskr Nor Laegeforen, 132(8), 952-955.

Brustugun, O. T., Møller, B., & Helland, A. (2014). Years of life lost as a measure of cancer burden on a national level. Br J Cancer, 111(5), 1014-1020. https://doi.org/10.1038/bjc.2014.364

Brustugun, O. T., Nilssen, Y., & Eide, I. J. Z. (2021). Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncol, 60(10), 1250-1256. https://doi.org/10.1080/0284186X.2021.1955971

Bugge, A. S., Lund, M. B., Valberg, M., Brustugun, O. T., Solberg, S., & Kongerud, J. (2018). Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. Eur J Cardiothorac Surg, 53(1), 221-227. https://doi.org/10.1093/ejcts/ezx274

Bunn, P. A., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., . . . Gandara, D. R. (1995). Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol, 13(7), 1632-1641.

Bunyaviroch, T., & Coleman, R. E. (2006). PET evaluation of lung cancer. J Nucl Med, 47(3), 451-469.

Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., . . . Shepherd, F. A. (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol, 28(1), 29-34. https://doi.org/10.1200/JCO.2009.24.0333

Bydder, S., Phillips, M., Joseph, D. J., Cameron, F., Spry, N. A., DeMelker, Y., & Musk, A. W. (2004). A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer, 91(1), 9-10.

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., . . . Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 397(10272), 375-386. https://doi.org/10.1016/S0140-6736(20)32714-8

Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., . . . Committee, B. T. S. S. o. C. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 70 Suppl 2, ii1-ii54. https://doi.org/10.1136/thoraxjnl-2015-207168

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & Group, C. P. (2013). Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA, 309(8), 814-822. https://doi.org/10.1001/jama.2013.879

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S., . . . Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 379(21), 2027-2039. https://doi.org/10.1056/NEJMoa1810171

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Hochmair, M. J., . . . Popat, S. (2020). Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol, 38(31), 3592-3603. https://doi.org/10.1200/JCO.20.00505

Camidge, D. R., Pabani, A., Miller, R. M., Rizvi, N. A., & Bazhenova, L. (2019). Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. J Thorac Oncol, 14(9), 1547-1555. https://doi.org/10.1016/j.jtho.2019.04.028

Cañizares, M. A., Matilla, J. M., Cueto, A., Algar, J., Muguruza, I., Moreno-Mata, N., . . . Members, E.-S. (2014). Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax, 69(7), 648-653. https://doi.org/10.1136/thoraxjnl-2013-204102

Cannon, D. M., Mehta, M. P., Adkison, J. B., Khuntia, D., Traynor, A. M., Tomé, W. A., . . . Cannon, G. M. (2013). Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol, 31(34), 4343-4348. https://doi.org/10.1200/JCO.2013.51.5353

Cao, C. Q., Yan, T. D., Bannon, P. G., & McCaughan, B. C. (2010). A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol, 5(10), 1692-1703. https://doi.org/10.1097/JTO.0b013e3181ed0489

Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., . . . participants, E. c. c. (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. https://doi.org/10.1093/annonc/mdv041

Cardillo, G., Sera, F., Di Martino, M., Graziano, P., Giunti, R., Carbone, L., . . . Martelli, M. (2004). Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg, 77(5), 1781-1785. https://doi.org/10.1016/j.athoracsur.2003.10.089

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., Groot, P. M., Truong, M. T., . . . Marom, E. M. (2017). IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics, 37(3), 758-776. https://doi.org/10.1148/rg.2017160096

Cavaliere, S., Venuta, F., Foccoli, P., Toninelli, C., & La Face, B. (1996). Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest, 110(6), 1536-1542.

Chalian, H., Töre, H. G., Horowitz, J. M., Salem, R., Miller, F. H., & Yaghmai, V. (2011). Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics, 31(7), 2093-2105. https://doi.org/10.1148/rg.317115050

Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Curr Treat Options Oncol, 17(5), 23. https://doi.org/10.1007/s11864-016-0397-1

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., . . . Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. https://doi.org/10.1016/S1470-2045(15)70168-3

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. (1995). BMJ, 311(7010), 899-909.

Chen, G., Huynh, M., Chen, A., Fehrenbacher, L., Gandara, D., & Lau, D. (2008). Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer, 9(1), 35-38.

Chen, G., Huynh, M., Fehrenbacher, L., West, H., Lara, P. N., Yavorkovsky, L. L., . . . Lau, D. (2009). Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol, 27(9), 1401-1404. https://doi.org/10.1200/JCO.2008.20.2127

Chen, L., Shen, C., Redmond, K. J., Page, B. R., Kummerlowe, M., Mcnutt, T., . . . Kleinberg, L. (2017). Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. Int J Radiat Oncol Biol Phys, 98(4), 939-947. https://doi.org/10.1016/j.ijrobp.2017.02.031

Cheng, S., Evans, W. K., Stys-Norman, D., & Shepherd, F. A. (2007). Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2(4), 348-354.

Cherny, N. I., Catane, R., Kosmidis, P., & Care, E. T. o. S. a. P. (2003). ESMO takes a stand on supportive and palliative care. Ann Oncol, 14(9), 1335-1337. https://doi.org/10.1093/annonc/mdg379

Chirieac, L. R., Pinkus, G. S., Pinkus, J. L., Godleski, J., Sugarbaker, D. J., & Corson, J. M. (2011). The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res, 1(1), 14-24.

Chiu, C. H., Chern, M. S., Wu, M. H., Hsu, W. H., Wu, Y. C., Huang, M. H., & Chang, S. C. (2003). Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg, 125(6), 1300-1305.

Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., . . . Wrona, A. (2017). ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol, 12(9), 1357-1367. https://doi.org/10.1016/j.jtho.2017.07.005

Cho, J., Kim, H. S., Ku, B. M., Choi, Y. L., Cristescu, R., Han, J., . . . Ahn, M. J. (2018). Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol, JCO2017773184. https://doi.org/10.1200/JCO.2017.77.3184

Christensen, N. L., Jekunen, A., Heinonen, S., Dalton, S. O., & Rasmussen, T. R. (2017). Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol, 56(7), 943-948. https://doi.org/10.1080/0284186X.2017.1315172

Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., . . . Ott, P. A. (2020). Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol, 15(4), 618-627. https://doi.org/10.1016/j.jtho.2019.12.109

Chung, J. H., Choe, G., Jheon, S., Sung, S. W., Kim, T. J., Lee, K. W., . . . Lee, C. T. (2009). Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol, 4(12), 1490-1495. https://doi.org/10.1097/JTO.0b013e3181bc9731

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13(3), 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0

Colt, H. G., Murgu, S. D., Korst, R. J., Slatore, C. G., Unger, M., & Quadrelli, S. (2013). Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e437S-454S. https://doi.org/10.1378/chest.12-2365

Corso, C. D., Rutter, C. E., Wilson, L. D., Kim, A. W., Decker, R. H., & Husain, Z. A. (2015). Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol, 10(1), 148-155. https://doi.org/10.1097/JTO.0000000000000406

Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P., Öberg, K., Eriksson, B., & Granberg, D. (2013). Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology, 98(2), 151-155. https://doi.org/10.1159/000354760

Cuffe, S., Booth, C. M., Peng, Y., Darling, G. E., Li, G., Kong, W., . . . Shepherd, F. A. (2012). Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol, 30(15), 1813-1821. https://doi.org/10.1200/JCO.2011.39.3330

D'Urso, V., Doneddu, V., Marchesi, I., Collodoro, A., Pirina, P., Giordano, A., & Bagella, L. (2013). Sputum analysis: non-invasive early lung cancer detection. J Cell Physiol, 228(5), 945-951. https://doi.org/10.1002/jcp.24263

de Langen, A. J., Raijmakers, P., Riphagen, I., Paul, M. A., & Hoekstra, O. S. (2006). The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg, 29(1), 26-29. https://doi.org/10.1016/j.ejcts.2005.10.002

De Leyn, P., Dooms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., . . . Zielinski, M. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg, 45(5), 787-798. https://doi.org/10.1093/ejcts/ezu028

de Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., . . . Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol, 27(9), 1413-1418. https://doi.org/10.1200/JCO.2008.17.5604

De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., . . . Lambin, P. (2009). Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol, 20(1), 98-102. https://doi.org/10.1093/annonc/mdn559

De Ruysscher, D., Nakagawa, K., & Asamura, H. (2014). Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. Eur Respir J, 44(2), 483-494. https://doi.org/10.1183/09031936.00020214

De Ruysscher, D., & Slotman, B. (2003). Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 68(3), 299-302.

De Wever, W., Stroobants, S., Coolen, J., & Verschakelen, J. A. (2009). Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J, 33(1), 201-212. https://doi.org/10.1183/09031936.00035108

Desai, R., Koipallil, G. K., Thomas, N., Mhaskar, R., Visweshwar, N., Laber, D., . . . Jaglal, M. (2020). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep, 10(1), 18945. https://doi.org/10.1038/s41598-020-75863-3

Detterbeck, F. C. (2010). Management of carcinoid tumors. Ann Thorac Surg, 89(3), 998-1005. https://doi.org/10.1016/j.athoracsur.2009.07.097

Detterbeck, F. C., Moran, C., Huang, J., Suster, S., Walsh, G., Kaiser, L., & Wick, M. (2011). Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thorac Oncol, 6(7 Suppl 3), S1730-1738. https://doi.org/10.1097/JTO.0b013e31821ea567

Detterbeck, F. C., Nicholson, A. G., Franklin, W. A., Marom, E. M., Travis, W. D., Girard, N., . . . Institutions, P. (2016). The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol, 11(5), 639-650. https://doi.org/10.1016/j.jtho.2016.01.024

Detterbeck, F. C., Nicholson, A. G., Kondo, K., Van Schil, P., & Moran, C. (2011). The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol, 6(7 Suppl 3), S1710-1716. https://doi.org/10.1097/JTO.0b013e31821e8cff

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., . . . investigators, t. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 271-282. https://doi.org/10.1016/S1470-2045(19)30691-6

Doebele, R. C., Perez, L., Trinh, H., Martinec, M., Martina, R., Riehl, T., . . . Crane, G. (2021). Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in. J Comp Eff Res, 10(17), 1271-1282. https://doi.org/10.2217/cer-2021-0131

Dominioni, L., Rotolo, N., Mantovani, W., Poli, A., Pisani, S., Conti, V., . . . Imperatori, A. (2012). A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. BMC Cancer, 12, 18. https://doi.org/10.1186/1471-2407-12-18

Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., . . . investigators, t. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 261-270. https://doi.org/10.1016/S1470-2045(19)30690-4

Drilon, A., Siena, S., Ou, S. I., Patel, M., Ahn, M. J., Lee, J., . . . De Braud, F. G. (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov, 7(4), 400-409. https://doi.org/10.1158/2159-8290.CD-16-1237

Du Rand, I. A., Barber, P. V., Goldring, J., Lewis, R. A., Mandal, S., Munavvar, M., . . . Group, B. T. S. I. B. G. (2011). British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax, 66 Suppl 3, iii1-21. https://doi.org/10.1136/thoraxjnl-2011-200713

Dziadziuszko, R., Krebs, M. G., De Braud, F., Siena, S., Drilon, A., Doebele, R. C., . . . Barlesi, F. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic. J Clin Oncol, 39(11), 1253-1263. https://doi.org/10.1200/JCO.20.03025

Edvardsen, E., Skjønsberg, O. H., Holme, I., Nordsletten, L., Borchsenius, F., & Anderssen, S. A. (2015). High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax, 70(3), 244-250. https://doi.org/10.1136/thoraxjnl-2014-205944

Eguren-Santamaria, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., . . . Gil-Bazo, I. (2020). PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clin Cancer Res, 26(16), 4186-4197. https://doi.org/10.1158/1078-0432.CCR-20-0798

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247. https://doi.org/10.1016/j.ejca.2008.10.026

Ellis, P., Davies, A. M., Evans, W. K., Haynes, A. E., Lloyd, N. S., & Care, L. C. D. S. G. o. C. C. O. s. P. i. E.-b. (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol, 1(6), 591-601.

Ernst, A., Feller-Kopman, D., Becker, H. D., & Mehta, A. C. (2004). Central airway obstruction. Am J Respir Crit Care Med, 169(12), 1278-1297.

Eze, C., Käsmann, L., & Manapov, F. (2019). Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. JAMA Oncol, 5(1), 11-12. https://doi.org/10.1001/jamaoncol.2018.4833

Fairchild, A., Harris, K., Barnes, E., Wong, R., Lutz, S., Bezjak, A., . . . Chow, E. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol, 26(24), 4001-4011.

Falcoz, P. E., Puyraveau, M., Thomas, P. A., Decaluwe, H., Hürtgen, M., Petersen, R. H., . . . Group, E. D. C. a. E. M. I. I. (2015). Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. https://doi.org/10.1093/ejcts/ezv154

Falk, S. J., Girling, D. J., White, R. J., Hopwood, P., Harvey, A., Qian, W., & Stephens, R. J. (2002). Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ, 325(7362), 465-465.

Falkson, C. B., Bezjak, A., Darling, G., Gregg, R., Malthaner, R., Maziak, D. E., . . . Care, L. C. D. S. G. o. C. C. O. s. P. i. E.-B. (2009). The management of thymoma: a systematic review and practice guideline. J Thorac Oncol, 4(7), 911-919.

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., . . . Group, P. S. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0

Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., . . . Investigators, I. (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)02098-5

Ferguson, M. K., & Lehman, A. G. (2003). Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg, 76(6), 1782-1788.

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. Int J Cancer. https://doi.org/10.1002/ijc.33588

Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., . . . Thomas, R. K. (2014). Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun, 5, 3518. https://doi.org/10.1038/ncomms4518

Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., . . . Von Roenn, J. H. (2009). Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol, 27(18), 3052-3058. https://doi.org/10.1200/JCO.2008.20.1558

Field, J. K., van Klaveren, R., Pedersen, J. H., Pastorino, U., Paci, E., Becker, N., . . . Group, E. R. S. T. (2013). European randomized lung cancer screening trials: Post NLST. J Surg Oncol, 108(5), 280-286. https://doi.org/10.1002/jso.23383

Filosso, P. L., Oliaro, A., Ruffini, E., Bora, G., Lyberis, P., Asioli, S., . . . Guerrera, F. (2013). Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol, 8(10), 1282-1288. https://doi.org/10.1097/JTO.0b013e31829f097a

Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., & Kramer, M. R. (2001). Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 119(6), 1647-1651.

Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E., Fleischmann, K. E., . . . Surgery, S. f. V. (2007). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation, 116(17), e418-499. https://doi.org/10.1161/CIRCULATIONAHA.107.185699

Fogh, S., & Yom, S. S. (2014). Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Semin Oncol, 41(6), 764-775. https://doi.org/10.1053/j.seminoncol.2014.09.020

Francis, S., Orton, A., Stoddard, G., Tao, R., Hitchcock, Y. J., Akerley, W., & Kokeny, K. E. (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, JCO2017744771. https://doi.org/10.1200/JCO.2017.74.4771

Fruh, M., Rolland, E., Pignon, J.-P., Seymour, L., Ding, K., Tribodet, H., . . . Shepherd, F. A. (2008). Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol, 26(21), 3573-3581.

Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., Felip, E., & Group, E. G. W. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi99-105. https://doi.org/10.1093/annonc/mdt178

Fujii, Y. (2011). Published guidelines for management of thymoma. Thorac Surg Clin, 21(1), 125-129, viii. https://doi.org/10.1016/j.thorsurg.2010.08.002

Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., . . . Garassino, M. C. (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 38(14), 1505-1517. https://doi.org/10.1200/JCO.19.03136

Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., . . . Ou, S. I. (2016). Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol, 34(34), 4079-4085. https://doi.org/10.1200/JCO.2016.68.4639

Gandhi, L., & Garassino, M. C. (2018). Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med, 379(11), e18. https://doi.org/10.1056/NEJMc1808567

Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., . . . Pérol, M. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 384(9944), 665-673. https://doi.org/10.1016/S0140-6736(14)60845-X

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., . . . Investigators, K.-. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 372(21), 2018-2028. https://doi.org/10.1056/NEJMoa1501824

Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., . . . Von Pawel, J. (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25(12), 1545-1552.

Genova, C., Rijavec, E., & Grossi, F. (2016). Hematopoietic growth factors in lung cancer. Curr Opin Oncol, 28(2), 135-144. https://doi.org/10.1097/CCO.0000000000000268

George, R., Jeba, J., Ramkumar, G., Chacko, A. G., & Tharyan, P. (2015). Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev, (9), CD006716. https://doi.org/10.1002/14651858.CD006716.pub3

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., . . . Brahmer, J. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol, 36(17), 1675-1684. https://doi.org/10.1200/JCO.2017.77.0412

Godoy, M. C., & Naidich, D. P. (2012). Overview and strategic management of subsolid pulmonary nodules. J Thorac Imaging, 27(4), 240-248. https://doi.org/10.1097/RTI.0b013e31825d515b

Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M., Griesinger, F., . . . Society, G. C. (2011). Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie, 65(1), 39-59. https://doi.org/10.1055/s-0030-1255961

Gollard, R., Jhatakia, S., Elliott, M., & Kosty, M. (2010). Large cell/neuroendocrine carcinoma. Lung Cancer, 69(1), 13-18. https://doi.org/10.1016/j.lungcan.2009.12.011

Gorenberg, M., Bar-Shalom, R., & Israel, O. (2008). Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol, 81(970), 821-825. https://doi.org/10.1259/bjr/26210052

Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013). Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e93S-120S. https://doi.org/10.1378/chest.12-2351

Granberg, D., Eriksson, B., Wilander, E., Grimfjärd, P., Fjällskog, M. L., Oberg, K., & Skogseid, B. (2001). Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol, 12(10), 1383-1391.

Grassi, L., Nanni, M. G., Rodin, G., Li, M., & Caruso, R. (2018). The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol, 29(1), 101-111. https://doi.org/10.1093/annonc/mdx526

Gray, S. G., & Mutti, L. (2020). Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res, 9(Suppl 1), S100-S119. https://doi.org/10.21037/tlcr.2019.11.23

Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J. V., Perrone, F., . . . De Marinis, F. (2008). Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 3(4), 430-440.

Gridelli, C., Peters, S., Sgambato, A., Casaluce, F., Adjei, A. A., & Ciardiello, F. (2014). ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev, 40(2), 300-306. https://doi.org/10.1016/j.ctrv.2013.07.002

Griffin, A. C., Schwartz, L. E., & Baloch, Z. W. (2011). Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal, 8, 20. https://doi.org/10.4103/1742-6413.90081

Gronberg, B. H., Bremnes, R. M., Flotten, O., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., . . . Sundstrom, S. (2009). Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 27(19), 3217-3224.

Groome, P. A., Bolejack, V., Crowley, J. J., Kennedy, C., Krasnik, M., Sobin, L. H., & Goldstraw, P. (2007). The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2(8), 694-705.

Grønberg, B. H., Halvorsen, T. O., Fløtten, Ø., Brustugun, O. T., Brunsvig, P. F., Aasebø, U., . . . Group, N. L. C. S. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol, 55(5), 591-597. https://doi.org/10.3109/0284186X.2015.1092584

Grønberg, B. H., Killingberg, K. T., Fløtten, Ø., Brustugun, O. T., Hornslien, K., Madebo, T., . . . Halvorsen, T. O. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol, 22(3), 321-331. https://doi.org/10.1016/S1470-2045(20)30742-7

Guckenberger, M., Mantel, F., Gerszten, P. C., Flickinger, J. C., Sahgal, A., Létourneau, D., . . . Kersh, R. (2014). Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol, 9, 226. https://doi.org/10.1186/s13014-014-0226-2

Guerra, L., De Ponti, E., Elisei, F., Bettinardi, V., Landoni, C., Picchio, M., . . . Messa, C. (2012). Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. Eur J Nucl Med Mol Imaging, 39(9), 1381-1390. https://doi.org/10.1007/s00259-012-2148-2

Gunluoglu, M. Z., Melek, H., Medetoglu, B., Demir, A., Kara, H. V., & Dincer, S. I. (2011). The validity of preoperative lymph node staging guidelines of European Society of Thoracic Surgeons in non-small-cell lung cancer patients. Eur J Cardiothorac Surg, 40(2), 287-290. https://doi.org/10.1016/j.ejcts.2010.11.030

Ha, D., Mazzone, P. J., Ries, A. L., Malhotra, A., & Fuster, M. (2016). The Utility of Exercise Testing in Patients with Lung Cancer. J Thorac Oncol, 11(9), 1397-1410. https://doi.org/10.1016/j.jtho.2016.04.021

Haldorsen, T., Andersen, A., & Boffetta, P. (2004). Smoking-adjusted incidence of lung cancer by occupation among Norwegian men. Cancer Causes Control, 15(2), 139-147. https://doi.org/10.1023/B:CACO.0000019485.74818.d6

Hamaji, M., Kojima, F., Omasa, M., Sozu, T., Sato, T., Chen, F., . . . Date, H. (2015). A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg, 47(4), 602-607. https://doi.org/10.1093/ejcts/ezu277

Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., . . . Oncology, U. (2008). Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol, 26(35), 5755-5760. https://doi.org/10.1200/JCO.2008.17.7840

Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008). Fleischner Society: glossary of terms for thoracic imaging. Radiology, 246(3), 697-722. https://doi.org/10.1148/radiol.2462070712

Haratake, N., & Seto, T. (2021). NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. Clin Lung Cancer, 22(1), 1-5. https://doi.org/10.1016/j.cllc.2020.10.013

Harpole, D. H., Feldman, J. M., Buchanan, S., Young, W. G., & Wolfe, W. G. (1992). Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg, 54(1), 50-54; discussion 54-55.

Helbekkmo, N., Sundstrom, S. H., Aasebo, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., . . . Bremnes, R. M. (2007). Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer, 97(3), 283-289. https://doi.org/6603869 [pii] 10.1038/sj.bjc.6603869

Helland, A., & Brustugun, O. T. (2009). [Lung cancer in smokers and never-smokers]. Tidsskr Nor Laegeforen, 129(18), 1859-1862. https://doi.org/1893600 [pii] 10.4045/tidsskr.08.0652 %/ Lungekreft hos roykere og aldri-roykere.

Helland, Å., Skaug, H. M., Kleinberg, L., Iversen, M. L., Rud, A. K., Fleischer, T., . . . Brustugun, O. T. (2011). EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol, 6(5), 947-950. https://doi.org/01243894-201105000-00016 [pii]


Helland, Å., Solberg, S., & Brustugun, O. T. (2012). Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol, 7(12), 1858-1861. https://doi.org/10.1097/JTO.0b013e318275b346

Hendriks, L. E., Hermans, B. C., van den Beuken-van Everdingen, M. H., Hochstenbag, M. M., & Dingemans, A. M. (2016). Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. J Thorac Oncol, 11(2), 155-173. https://doi.org/10.1016/j.jtho.2015.10.001

Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., . . . Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387(10027), 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., . . . Johnson, D. H. (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 22(5), 785-794.

Herder, G. J., van Tinteren, H., Golding, R. P., Kostense, P. J., Comans, E. F., Smit, E. F., & Hoekstra, O. S. (2005). Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 128(4), 2490-2496. https://doi.org/10.1378/chest.128.4.2490

Hermes, A., Bergman, B., Bremnes, R., Ek, L., Fluge, S., Sederholm, C., . . . Sorenson, S. (2008). Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol, 26(26), 4261-4267.

Herth, F., Becker, H. D., & Ernst, A. (2004). Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial. Chest, 125(1), 322-325.

Herth, F. J., Eberhardt, R., Krasnik, M., & Ernst, A. (2008). Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest, 133(4), 887-891. https://doi.org/10.1378/chest.07-2535

Herth, F. J., Ernst, A., Eberhardt, R., Vilmann, P., Dienemann, H., & Krasnik, M. (2006). Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J, 28(5), 910-914. https://doi.org/10.1183/09031936.06.00124905

Hillerdal, G., Sorensen, J. B., Sundstrom, S., Riska, H., Vikstrom, A., & Hjerpe, A. (2008). Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol, 3(11), 1325-1331.

Hishida, T., Nagai, K., Yoshida, J., Nishimura, M., Ishii, G.-i., Iwasaki, M., & Nishiwaki, Y. (2006). Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg, 131(4), 838-842.

Hochmair, M., Weinlinger, C., Schwab, S., Naber, J., Setinek, U., Krenbek, D., . . . Burghuber, O. C. (2019). Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anticancer Drugs, 30(7), e0787. https://doi.org/10.1097/CAD.0000000000000787

Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., . . . van Meerbeeck, J. P. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol, 30(13), 1541-1549. https://doi.org/10.1200/JCO.2011.39.6671

Holsti, L. R., Pyrhonen, S., Kajanti, M., Mantyla, M., Mattson, K., Maasilta, P., & Kivisaari, L. (1997). Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol, 36(4), 397-405.

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., . . . Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol, 21(4), 531-540. https://doi.org/10.1016/S1470-2045(19)30856-3

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., . . . Group, I. S. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med, 379(23), 2220-2229. https://doi.org/10.1056/NEJMoa1809064

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (Writers). (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

Huang, J., Detterbeck, F. C., Wang, Z., & Loehrer, P. J. (2011). Standard outcome measures for thymic malignancies. J Thorac Oncol, 6(7 Suppl 3), S1691-1697. https://doi.org/10.1097/JTO.0b013e3182254ac1

Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., . . . Camidge, D. R. (2020). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol, 15(3), 404-415. https://doi.org/10.1016/j.jtho.2019.11.004

Hui, D., & Bruera, E. (2016). Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol, 13(3), 159-171. https://doi.org/10.1038/nrclinonc.2015.201

Husain, A. N., Colby, T., Ordonez, N., Krausz, T., Attanoos, R., Beasley, M. B., . . . Group, I. M. I. (2013). Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, 137(5), 647-667. https://doi.org/10.5858/arpa.2012-0214-OA

Haasbeek, C. J. A., Senan, S., Smit, E. F., Paul, M. A., Slotman, B. J., & Lagerwaard, F. J. (2008). Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist, 13(3), 309-319.

Igawa, S., Watanabe, R., Ito, I., Murakami, H., Takahashi, T., Nakamura, Y., . . . Kameya, T. (2010). Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer, 68(3), 438-445. https://doi.org/10.1016/j.lungcan.2009.07.003

Ignatius Ou, S. H., & Zell, J. A. (2009). The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol, 4(3), 300-310. https://doi.org/10.1097/JTO.0b013e318194a355

Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., . . . Hagiwara, K. (2009). First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 27(9), 1394-1400.

Iyoda, A., Hiroshima, K., Moriya, Y., Iwadate, Y., Takiguchi, Y., Uno, T., . . . Yoshino, I. (2009). Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg, 138(2), 446-453. https://doi.org/10.1016/j.jtcvs.2008.12.037

Jakopovic, M., Bitar, L., Seiwerth, F., Marusic, A., Krpina, K., & Samarzija, M. (2020). Immunotherapy for thymoma. J Thorac Dis, 12(12), 7635-7641. https://doi.org/10.21037/jtd-2019-thym-12

Janni, W., Kiechle, M., Sommer, H., Rack, B., Gauger, K., Heinrigs, M., . . . Group, A. S. (2006). Study participation improves treatment strategies and individual patient care in participating centers. Anticancer Res, 26(5B), 3661-3667.

Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S., & Broadley, K. E. (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57(11), 939-944. https://doi.org/10.1136/thorax.57.11.939

Jensen, L. H., Osterlind, K., & Rytter, C. (2008). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 62(1), 85-91.

Johnson, D. B., Chandra, S., & Sosman, J. A. (2018). Immune Checkpoint Inhibitor Toxicity in 2018. JAMA, 320(16), 1702-1703. https://doi.org/10.1001/jama.2018.13995

Johnson, P. T., Horton, K. M., & Fishman, E. K. (2009). Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics, 29(5), 1333-1351. https://doi.org/10.1148/rg.295095027

Kantor, T., & Wakeam, E. (2021). Landmark Trials in the Surgical Management of Mesothelioma. Ann Surg Oncol. https://doi.org/10.1245/s10434-021-09589-5

Kao, S. C., Yan, T. D., Lee, K., Burn, J., Henderson, D. W., Klebe, S., . . . McCaughan, B. C. (2011). Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol, 6(3), 602-605. https://doi.org/10.1097/JTO.0b013e31820ce2c7

Karlsson, A., Brunnström, H., Lindquist, K. E., Jirström, K., Jönsson, M., Rosengren, F., . . . Staaf, J. (2015). Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 6(26), 22028-22037. https://doi.org/10.18632/oncotarget.4314

Kauczor, H. U., Bonomo, L., Gaga, M., Nackaerts, K., Peled, N., Prokop, M., . . . (ERS), E. R. S. (2015). ESR/ERS white paper on lung cancer screening. Eur Respir J, 46(1), 28-39. https://doi.org/10.1183/09031936.00033015

Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., . . . Gandara, D. R. (2008). Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 26(15), 2450-2456. https://doi.org/10.1200/JCO.2007.14.4824

Kelly, R. J. (2013). Thymoma versus thymic carcinoma: differences in biology impacting treatment. J Natl Compr Canc Netw, 11(5), 577-583.

Kelly, R. J., Sharon, E., & Hassan, R. (2011). Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 73(3), 256-263. https://doi.org/10.1016/j.lungcan.2011.04.014

Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., . . . Tsuboi, M. (2020). Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 38(19), 2187-2196. https://doi.org/10.1200/JCO.19.02674

Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. (2019). Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. J Natl Compr Canc Netw, 17(6), 750-757. https://doi.org/10.6004/jnccn.2019.7310

Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., . . . Shaw, A. T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(15)00614-2

Kim, D. W., Tiseo, M., Ahn, M. J., Reckamp, K. L., Hansen, K. H., Kim, S. W., . . . Camidge, D. R. (2017). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol, 35(22), 2490-2498. https://doi.org/10.1200/JCO.2016.71.5904

Klimstra, D. S., Modlin, I. R., Coppola, D., Lloyd, R. V., & Suster, S. (2010). The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas, 39(6), 707-712. https://doi.org/10.1097/MPA.0b013e3181ec124e

Kodama, K., Doi, O., Higashiyama, M., & Yokouchi, H. (1997). Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg, 114(3), 347-353.

Komaki, R., & Gomez, D. R. (2014). Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Front Oncol, 3, 330. https://doi.org/10.3389/fonc.2013.00330

Konge, L., Vilmann, P., Clementsen, P., Annema, J. T., & Ringsted, C. (2012). Reliable and valid assessment of competence in endoscopic ultrasonography and fine-needle aspiration for mediastinal staging of non-small cell lung cancer. Endoscopy, 44(10), 928-933. https://doi.org/10.1055/s-0032-1309892

Korse, C. M., Taal, B. G., Vincent, A., van Velthuysen, M. L., Baas, P., Buning-Kager, J. C., . . . Bonfrer, J. M. (2012). Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer, 48(5), 662-671. https://doi.org/10.1016/j.ejca.2011.08.012

Korst, R. J., Bezjak, A., Blackmon, S., Choi, N., Fidias, P., Liu, G., . . . Keshavjee, S. (2014). Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg, 147(1), 36-44, 46.e31. https://doi.org/10.1016/j.jtcvs.2013.08.061

Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013). Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e369S-e399S. https://doi.org/10.1378/chest.12-2362

Kozuki, T., Fujimoto, N., Ueoka, H., Kiura, K., Fujiwara, K., Shiomi, K., . . . Tanimoto, M. (2005). Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol, 131(3), 147-151. https://doi.org/10.1007/s00432-004-0626-z

Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., . . . investigators, T. (2013). Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol, 24(4), 986-992. https://doi.org/10.1093/annonc/mds578

Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., . . . Vogelzang, N. J. (2009). Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol, 27(18), 3007-3013. https://doi.org/10.1200/JCO.2008.20.3943

Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., . . . Fuchs, C. S. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 26(20), 3403-3410. https://doi.org/10.1200/JCO.2007.15.9020

Kumar, A., Weber, M. H., Gokaslan, Z., Wolinsky, J. P., Schmidt, M., Rhines, L., . . . Fisher, C. G. (2017). Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clin Spine Surg, 30(4), 156-163. https://doi.org/10.1097/BSD.0000000000000528

Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., . . . Lundeby, T. (2018). Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol, 19(11), e588-e653. https://doi.org/10.1016/S1470-2045(18)30415-7

Lad, T., Piantadosi, S., Thomas, P., Payne, D., Ruckdeschel, J., & Giaccone, G. (1994). A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest, 106(6 Suppl), 320S-323S.

Lakha, S., Gomez, J. E., Flores, R. M., & Wisnivesky, J. P. (2014). Prognostic significance of visceral pleural involvement in early-stage lung cancer. Chest, 146(6), 1619-1626. https://doi.org/10.1378/chest.14-0204

Lamba, N., Muskens, I. S., DiRisio, A. C., Meijer, L., Briceno, V., Edrees, H., . . . Broekman, M. L. (2017). Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol, 12(1), 106. https://doi.org/10.1186/s13014-017-0840-x

Langer, A. (2010). A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res, 10, 283. https://doi.org/10.1186/1472-6963-10-283

Le Péchoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., . . . Group, P. C. I. P. C. (2009). Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 10(5), 467-474. https://doi.org/10.1016/S1470-2045(09)70101-9

Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., . . . Group, P. C. I. P. C. (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol, 22(5), 1154-1163. https://doi.org/10.1093/annonc/mdq576

Le Treut, J., Sault, M. C., Lena, H., Souquet, P. J., Vergnenegre, A., Le Caer, H., . . . Chouaid, C. (2013). Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol, 24(6), 1548-1552. https://doi.org/10.1093/annonc/mdt009

Le, X., Desai, N. V., Majid, A., Karp, R. S., Huberman, M. S., Rangachari, D., . . . Costa, D. B. (2015). De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer, 88(1), 70-73. https://doi.org/10.1016/j.lungcan.2015.02.003

Lee, H. S., Lee, G. K., Kim, M. S., Lee, J. M., Kim, H. Y., Nam, B. H., . . . Hwangbo, B. (2008). Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest, 134(2), 368-374. https://doi.org/10.1378/chest.07-2105

Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., . . . Goldman, L. (1999). Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation, 100(10), 1043-1049.

Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., . . . Awad, M. M. (2018). Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol, 36(19), 1905-1912. https://doi.org/10.1200/JCO.2017.77.0305

Li, A., Garcia, D. A., Lyman, G. H., & Carrier, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res, 173, 158-163. https://doi.org/10.1016/j.thromres.2018.02.144

Liao, Z., Lee, J. J., Komaki, R., Gomez, D. R., O'Reilly, M. S., Fossella, F. V., . . . Mohan, R. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 36(18), 1813-1822. https://doi.org/10.1200/JCO.2017.74.0720

Lilenbaum, R., Axelrod, R., Thomas, S., Dowlati, A., Seigel, L., Albert, D., . . . Botkin, D. (2008). Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol, 26(6), 863-869.

Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., . . . Ireland, S. f. C. S. i. G. B. a. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. https://doi.org/10.1136/thx.2010.145938

Lim, S. M., Kim, H. R., Lee, J. S., Lee, K. H., Lee, Y. G., Min, Y. J., . . . Cho, B. C. (2017). Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol, 35(23), 2613-2618. https://doi.org/10.1200/JCO.2016.71.3701

Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., . . . Borczuk, A. C. (2015). Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol. https://doi.org/10.1200/JCO.2015.62.0674

Loehrer, P. J., Wang, W., Johnson, D. H., Aisner, S. C., Ettinger, D. S., & Trial, E. C. O. G. P. I. (2004). Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol, 22(2), 293-299. https://doi.org/10.1200/JCO.2004.02.047

Lou, F., Huang, J., Sima, C. S., Dycoco, J., Rusch, V., & Bach, P. B. (2013). Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg, 145(1), 75-81; discussion 81-72. https://doi.org/10.1016/j.jtcvs.2012.09.030

Lund-Iversen, M., Grøholt, K. K., Helland, Å., Borgen, E., & Brustugun, O. T. (2015). NUT expression in primary lung tumours. Diagn Pathol, 10, 156. https://doi.org/10.1186/s13000-015-0395-9

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., . . . Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-2139.

Mackley, H. B., & Videtic, G. M. (2006). Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park), 20(12), 1537-1543; discussion 1544-1535, 1549.

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., . . . Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243. https://doi.org/10.1148/radiol.2017161659

MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., . . . Jeremic, B. (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol, 91(1), 85-94.

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., . . . Nukiwa, T. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362(25), 2380-2388. https://doi.org/362/25/2380 [pii] 10.1056/NEJMoa0909530

Makino, T., Mikami, T., Hata, Y., Otsuka, H., Koezuka, S., Isobe, K., . . . Iyoda, A. (2016). Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. Ann Thorac Surg, 102(5), 1694-1701. https://doi.org/10.1016/j.athoracsur.2016.04.100

Manhire, A., Charig, M., Clelland, C., Gleeson, F., Miller, R., Moss, H., . . . BTS. (2003). Guidelines for radiologically guided lung biopsy. Thorax, 58(11), 920-936.

Manhire, A. R., Richardson, C. M., & Gleeson, F. V. (2003). Lung biopsy guidelines--for the obedience of fools and guidance of wise men. Thorax, 58(11), 913-914.

Mao, J., Kocak, Z., Zhou, S., Garst, J., Evans, E. S., Zhang, J., . . . Marks, L. B. (2007). The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. Int J Radiat Oncol Biol Phys, 67(5), 1360-1369. https://doi.org/10.1016/j.ijrobp.2006.11.003

Marchevsky, A., Marx, A., Ströbel, P., Suster, S., Venuta, F., Marino, M., . . . Zakowski, M. (2011). Policies and reporting guidelines for small biopsy specimens of mediastinal masses. J Thorac Oncol, 6(7 Suppl 3), S1724-1729. https://doi.org/10.1097/JTO.0b013e31821ea57c

Marinaccio, A., Binazzi, A., Cauzillo, G., Cavone, D., Zotti, R. D., Ferrante, P., . . . Tumino, R. (2007). Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer, 43(18), 2722-2728. https://doi.org/S0959-8049(07)00748-4 [pii] 10.1016/j.ejca.2007.09.018

Marom, E. M. (2013). Advances in thymoma imaging. J Thorac Imaging, 28(2), 69-80; quiz 81-63. https://doi.org/10.1097/RTI.0b013e31828609a0

Masaoka, A. (2010). Staging system of thymoma. J Thorac Oncol, 5(10 Suppl 4), S304-312. https://doi.org/10.1097/JTO.0b013e3181f20c05

Matheos, T., Ram, L., & Canelli, R. (2020). Preoperative Evaluation for Thoracic Surgery. Thorac Surg Clin, 30(3), 241-247. https://doi.org/10.1016/j.thorsurg.2020.04.003

Matsumoto, R., Takamori, S., Yokoyama, S., Hashiguchi, T., Murakami, D., Yoshiyama, K., . . . Akagi, Y. (2018). Lung function in the late postoperative phase and influencing factors in patients undergoing pulmonary lobectomy. J Thorac Dis, 10(5), 2916-2923. https://doi.org/10.21037/jtd.2018.05.27

McKenna, R. J., Mahtabifard, A., Yap, J., McKenna, R., Fuller, C., Merhadi, A., & Hakimian, B. (2008). Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg, 85(2), 733-736.

Mehta, V. (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63(1), 5-24. https://doi.org/10.1016/j.ijrobp.2005.03.047

Mesko, S., & Gomez, D. (2018). Proton Therapy in Non-small Cell Lung Cancer. Curr Treat Options Oncol, 19(12), 76. https://doi.org/10.1007/s11864-018-0588-z

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., . . . Group, W. J. O. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 11(2), 121-128. https://doi.org/10.1016/S1470-2045(09)70364-X

Moertel, C. G., & Hanley, J. A. (1979). Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials, 2(4), 327-334.

Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68(2), 227-232.

Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Wu, Y. L. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol, 36(22), 2244-2250. https://doi.org/10.1200/JCO.2018.78.7994

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., . . . Investigators, A. (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376(7), 629-640. https://doi.org/10.1056/NEJMoa1612674

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., . . . Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361(10), 947-957.

Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., . . . Investigators, K.-. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183), 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7

Mollberg, N. M., & Ferguson, M. K. (2013). Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg, 95(3), 1112-1121. https://doi.org/10.1016/j.athoracsur.2012.09.075

Moore, W., Freiberg, E., Bishawi, M., Halbreiner, M. S., Matthews, R., Baram, D., & Bilfinger, T. V. (2013). FDG-PET imaging in patients with pulmonary carcinoid tumor. Clin Nucl Med, 38(7), 501-505. https://doi.org/10.1097/RLU.0b013e318279f0f5

Munavvar, M., Khan, M. A., Edwards, J., Waqaruddin, Z., & Mills, J. (2007). The autoclavable semirigid thoracoscope: the way forward in pleural disease? Eur Respir J, 29(3), 571-574. https://doi.org/10.1183/09031936.00101706

Naidich, D. P., Bankier, A. A., MacMahon, H., Schaefer-Prokop, C. M., Pistolesi, M., Goo, J. M., . . . Travis, W. D. (2013). Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology, 266(1), 304-317. https://doi.org/10.1148/radiol.12120628

Nantavithya, C., Gomez, D. R., Wei, X., Komaki, R., Liao, Z., Lin, S. H., . . . Chang, J. Y. (2018). Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 101(3), 558-563. https://doi.org/10.1016/j.ijrobp.2018.02.022

Narayan, S., & Thomas, C. R., Jr. (2006). Multimodality therapy for Pancoast tumor. Nat Clin Pract Oncol, 3(9), 484-491.

Neyman, K., Sundset, A., Naalsund, A., Espinoza, A., Solberg, S., Kongerud, J., & Fosse, E. (2012). Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchology Interv Pulmonol, 19(1), 29-34. https://doi.org/10.1097/LBR.0b013e3182446b52

Nezu, K., Kushibe, K., Tojo, T., Takahama, M., & Kitamura, S. (1998). Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest, 113(6), 1511-1516.

Nguyen, Q. N., Chun, S. G., Chow, E., Komaki, R., Liao, Z., Zacharia, R., . . . Lewis, V. O. (2019). Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.0192

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013). Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res, 19(14), 3936-3943. https://doi.org/10.1158/1078-0432.CCR-13-0895

Noonan, C. W. (2017). Environmental asbestos exposure and risk of mesothelioma. Ann Transl Med, 5(11), 234. https://doi.org/10.21037/atm.2017.03.74

Nussbaum, D. P., Speicher, P. J., Gulack, B. C., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2015). Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg, 99(2), 428-434. https://doi.org/10.1016/j.athoracsur.2014.08.030

O'Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cuceviá, B., Juhasz, G., . . . Crofts, T. (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol, 24(34), 5441-5447. https://doi.org/10.1200/JCO.2006.06.5821

O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., . . . Sayer, R. (2006). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol, 17(2), 270-275. https://doi.org/10.1093/annonc/mdj073

O'Rourke, N., Garcia, J. C., Paul, J., Lawless, C., McMenemin, R., & Hill, J. (2007). A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol, 84(1), 18-22.

Oberg, K., & Castellano, D. (2011). Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev, 30 Suppl 1, 3-7. https://doi.org/10.1007/s10555-011-9292-1

Oberg, K., Hellman, P., Kwekkeboom, D., Jelic, S., & Group, E. G. W. (2010). Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v220-222. https://doi.org/10.1093/annonc/mdq191

Oh, J. R., Seo, J. H., Chong, A., Min, J. J., Song, H. C., Kim, Y. C., & Bom, H. S. (2012). Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging, 39(6), 925-935. https://doi.org/10.1007/s00259-011-2059-7

Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., . . . Team, P. P. (2011). Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA, 306(17), 1865-1873. https://doi.org/10.1001/jama.2011.1591

Okumura, M., Ohta, M., Tateyama, H., Nakagawa, K., Matsumura, A., Maeda, H., . . . Masaoka, A. (2002). The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer, 94(3), 624-632.

Ou, S. H., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C., Hughes, B., . . . Kim, D. W. (2016). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol, 34(7), 661-668. https://doi.org/10.1200/jco.2015.63.9443

Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., . . . O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer, 132, 187-198. https://doi.org/10.1016/j.ejca.2020.03.006

Pancoast, H. (1932). Superior pulmonary sulcus tumor. JAMA, 99, 1391-1396.

Park, C. M., Goo, J. M., Kim, T. J., Lee, H. J., Lee, K. W., Lee, C. H., . . . Im, J. G. (2008). Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions? Chest, 133(6), 1402-1409. https://doi.org/10.1378/chest.07-2568

Park, E. A., Goo, J. M., Lee, J. W., Kang, C. H., Lee, H. J., Lee, C. H., . . . Im, J. G. (2009). Efficacy of computer-aided detection system and thin-slab maximum intensity projection technique in the detection of pulmonary nodules in patients with resected metastases. Invest Radiol, 44(2), 105-113. https://doi.org/10.1097/RLI.0b013e318190fcfc

Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., . . . Paz-Ares, L. (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(16)30033-X

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., . . . Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-648.

Patel, S. H., Robbins, J. R., Gore, E. M., Bradley, J. D., Gaspar, L. E., Germano, I., . . . Metastases, E. P. o. R. O. B. (2012). ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol, 35(3), 302-306. https://doi.org/10.1097/COC.0b013e31824be246

Payne, C., Larkin, P. J., McIlfatrick, S., Dunwoody, L., & Gracey, J. H. (2013). Exercise and nutrition interventions in advanced lung cancer: a systematic review. Curr Oncol, 20(4), e321-337. https://doi.org/10.3747/co.20.1431

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., . . . investigators, C. (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 394(10212), 1929-1939. https://doi.org/10.1016/S0140-6736(19)32222-6

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., . . . Investigators, K.-. (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 379(21), 2040-2051. https://doi.org/10.1056/NEJMoa1810865

Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., . . . Halmos, B. (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol, 15(10), 1657-1669. https://doi.org/10.1016/j.jtho.2020.06.015

Pedersen, J. H., Sørensen, J. B., Saghir, Z., Fløtten, Ø., Brustugun, O. T., Ashraf, H., . . . Gudbjartsson, T. (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncol, 56(10), 1249-1257. https://doi.org/10.1080/0284186X.2017.1329592

Pelayo Alvarez, M., Gallego Rubio, O., Bonfill Cosp, X., & Agra Varela, Y. (2009). Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev, (4), CD001990. https://doi.org/10.1002/14651858.CD001990.pub2

Perigaud, C., Bridji, B., Roussel, J. C., Sagan, C., Mugniot, A., Duveau, D., . . . Despins, P. (2009). Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg, 36(4), 731-736. https://doi.org/10.1016/j.ejcts.2009.05.044

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W., . . . Investigators, A. T. (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1704795

Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., . . . Lebeau, B. (1992). A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med, 327(23), 1618-1624.

Pijls-Johannesma, M. C. G., De Ruysscher, D., Lambin, P., Rutten, I., & Vansteenkiste, J. F. (2005). Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev, (1).

Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., . . . Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol, 17(7), 984-993. https://doi.org/10.1016/S1470-2045(16)30146-2

Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., . . . Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 18(10), 1307-1316. https://doi.org/10.1016/S1470-2045(17)30679-4

Polanski, J., Jankowska-Polanska, B., Rosinczuk, J., Chabowski, M., & Szymanska-Chabowska, A. (2016). Quality of life of patients with lung cancer. Onco Targets Ther, 9, 1023-1028. https://doi.org/10.2147/OTT.S100685

Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., . . . (ESA), E. S. o. A. (2010). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol, 27(2), 92-137. https://doi.org/10.1097/EJA.0b013e328334c017

Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., . . . Committee, E. G. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28(suppl_4), iv1-iv21. https://doi.org/10.1093/annonc/mdx222

Pozzessere, C., Lazor, R., Jumeau, R., Peters, S., Prior, J. O., & Beigelman-Aubry, C. (2021). Imaging Features of Pulmonary Immune-related Adverse Events. J Thorac Oncol, 16(9), 1449-1460. https://doi.org/10.1016/j.jtho.2021.05.017

Prelaj, A., Pircher, C. C., Massa, G., Martelli, V., Corrao, G., Lo Russo, G., . . . Rebuzzi, S. E. (2021). Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers (Basel), 13(6). https://doi.org/10.3390/cancers13061300

Pujol, J. L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., . . . Souquet, P. J. (2019). A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. J Thorac Oncol, 14(5), 903-913. https://doi.org/10.1016/j.jtho.2019.01.008

Rajan, A., Carter, C. A., Berman, A., Cao, L., Kelly, R. J., Thomas, A., . . . Giaccone, G. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol, 15(2), 191-200. https://doi.org/10.1016/S1470-2045(13)70596-5

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., . . . Investigators, F. (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med, 382(1), 41-50. https://doi.org/10.1056/NEJMoa1913662

Raman, V., Jawitz, O. K., Yang, C. J., Tong, B. C., D'Amico, T. A., Berry, M. F., & Harpole, D. H. (2019). Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Ann Thorac Surg, 108(2), 377-383. https://doi.org/10.1016/j.athoracsur.2019.03.053

Raman, V., Jawitz, O. K., Yang, C. J., Voigt, S. L., Tong, B. C., D'Amico, T. A., & Harpole, D. H. (2019). Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol, 14(12), 2143-2151. https://doi.org/10.1016/j.jtho.2019.09.005

Ray, M., & Kindler, H. L. (2009). Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest, 136(3), 888-896. https://doi.org/10.1378/chest.08-2665

Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., . . . Group, L.-L. S. (2014). Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 15(2), 143-155. https://doi.org/10.1016/S1470-2045(13)70586-2

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., . . . Group, I. S. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med, 7(5), 387-401. https://doi.org/10.1016/S2213-2600(19)30084-0

Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., Peters, S., & Group, E. G. W. (2014). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25 Suppl 3, iii27-39. https://doi.org/10.1093/annonc/mdu199

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., . . . Investigators, K.-. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375(19), 1823-1833. https://doi.org/10.1056/NEJMoa1606774

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., . . . Group, B. S. (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol, 21(9), 1804-1809. https://doi.org/10.1093/annonc/mdq020

Refai, M., Brunelli, A., Salati, M., Pompili, C., Xiumè, F., & Sabbatini, A. (2011). Efficacy of anterior fissureless technique for right upper lobectomies: a case-matched analysis. Eur J Cardiothorac Surg, 39(6), 1043-1046. https://doi.org/10.1016/j.ejcts.2010.09.039

Reveiz, L., Rueda, J. R., & Cardona, A. F. (2012). Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev, 12, CD004284. https://doi.org/10.1002/14651858.CD004284.pub3

Rheinheimer, S., Heussel, C. P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., . . . Christopoulos, P. (2020). Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers (Basel), 12(4). https://doi.org/10.3390/cancers12041046

Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019). Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol, JCO1900189. https://doi.org/10.1200/JCO.19.00189

Rieber, J., Schmitt, J., Warth, A., Muley, T., Kappes, J., Eichhorn, F., . . . Rieken, S. (2015). Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res, 20, 64. https://doi.org/10.1186/s40001-015-0158-9

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., . . . Group, O. S. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., . . . Hodi, F. S. (2018). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol, 36(17), 1668-1674. https://doi.org/10.1200/JCO.2017.75.6270

Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., . . . Chirieac, L. R. (2009). Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, 15(16), 5216-5223. https://doi.org/10.1158/1078-0432.CCR-09-0802

Romi, F. (2011). Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis, 2011, 474512. https://doi.org/10.4061/2011/474512

Romi, F., Skeie, G. O., Aarli, J. A., & Gilhus, N. E. (2000). Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol, 247(5), 369-375.

Ropper, A. E., & Ropper, A. H. (2017). Acute Spinal Cord Compression. N Engl J Med, 376(14), 1358-1369. https://doi.org/10.1056/NEJMra1516539

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., . . . Taron, M. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 361(10), 958-967.

Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., . . . Brambilla, E. (2005). Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol, 23(34), 8774-8785. https://doi.org/10.1200/JCO.2005.02.8233

Rostad, H., Naalsund, A., Jacobsen, R., Strand, T. E., Scott, H., Heyerdahl Strøm, E., & Norstein, J. (2004). Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg, 26(4), 782-786. https://doi.org/10.1016/j.ejcts.2004.06.011

Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., & Eagan, T. M. (2008). Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulm Med, 8, 2. https://doi.org/10.1186/1471-2466-8-2

Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., & Eagan, T. M. (2009). Cost minimization analysis for combinations of sampling techniques in bronchoscopy of endobronchial lesions. Respir Med, 103(6), 888-894. https://doi.org/10.1016/j.rmed.2008.12.012

Rowell, N. P., & Gleeson, F. V. (2001). Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev, (4), CD001316.

Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., . . . America, I. D. S. o. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 58(3), e44-100. https://doi.org/10.1093/cid/cit684

Rubins, J., Unger, M., Colice, G. L., & Physicians, A. C. o. C. (2007). Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest, 132(3 Suppl), 355S-367S. https://doi.org/10.1378/chest.07-1390

Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., . . . Investigators, K.-. (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol, 38(21), 2369-2379. https://doi.org/10.1200/JCO.20.00793

Rudin, C. M., Ismaila, N., Hann, C. L., Malhotra, N., Movsas, B., Norris, K., . . . Giaccone, G. (2015). Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol, 33(34), 4106-4111. https://doi.org/10.1200/JCO.2015.63.7918

Ruffini, E., Detterbeck, F., Van Raemdonck, D., Rocco, G., Thomas, P., Weder, W., . . . Venuta, F. (2014). Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. J Thorac Oncol, 9, 541–548.

Ruffini, E., Van Raemdonck, D., Detterbeck, F., Rocco, G., Thomas, P., Venuta, F., & Group, E. S. o. T. S. T. Q. W. (2011). Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol, 6(3), 614-623. https://doi.org/10.1097/JTO.0b013e318207cd74

Rusch, V. W. (2006). Management of Pancoast tumours. Lancet Oncol, 7(12), 997-1005.

Rusch, V. W., Chansky, K., Kindler, H. L., Nowak, A. K., Pass, H. I., Rice, D. C., . . . IASLC Staging and Prognostic Factors Committee, a. b., and participating institutions. (2016). The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol, 11(12), 2112-2119. https://doi.org/10.1016/j.jtho.2016.09.124

Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., . . . Gandara, D. (2007). Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol, 25(3), 313-318.

Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., . . . Robin, T. P. (2020). Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol, 6(7), 1028-1037. https://doi.org/10.1001/jamaoncol.2020.1271

Sadikov, E., Bezjak, A., Yi, Q. L., Wells, W., Dawson, L., Millar, B. A., & Laperriere, N. (2007). Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol), 19(7), 532-538. https://doi.org/10.1016/j.clon.2007.06.001

Sagerup, C. M., Nymoen, D. A., Halvorsen, A. R., Lund-Iversen, M., Helland, A., & Brustugun, O. T. (2014). Human papilloma virus detection and typing in 334 lung cancer patients. Acta Oncol, 53(7), 952-957. https://doi.org/10.3109/0284186X.2013.879608

Sagerup, C. M., Smastuen, M., Johannesen, T. B., Helland, A., & Brustugun, O. T. (2012). Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients. J Thorac Oncol, 7(1), 57-63. https://doi.org/10.1097/JTO.0b013e3182307f7e

Sagerup, C. M., Småstuen, M., Johannesen, T. B., Helland, Å., & Brustugun, O. T. (2011). Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax, 66(4), 301-307. https://doi.org/thx.2010.151621 [pii]


Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., . . . Pedersen, J. H. (2012). CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax, 67(4), 296-301. https://doi.org/10.1136/thoraxjnl-2011-200736

Saji, H., Tsuboi, M., Matsubayashi, J., Miyajima, K., Shimada, Y., Imai, K., . . . Ikeda, N. (2010). Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs, 21(1), 89-93. https://doi.org/10.1097/CAD.0b013e328330fd79

Salati, M., & Brunelli, A. (2012). Preoperative assessment of patients for lung cancer surgery. Curr Opin Pulm Med, 18(4), 289-294. https://doi.org/10.1097/MCP.0b013e3283539776

Salati, M., & Brunelli, A. (2016). Risk Stratification in Lung Resection. Curr Surg Rep, 4(11), 37. https://doi.org/10.1007/s40137-016-0158-x

Salazar, M. C., Rosen, J. E., Wang, Z., Arnold, B. N., Thomas, D. C., Herbst, R. S., . . . Boffa, D. J. (2017). Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncol, 3(5), 610-619. https://doi.org/10.1001/jamaoncol.2016.5829

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., . . . Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355(24), 2542-2550.

Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., . . . Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol, 3(7), 756-763. https://doi.org/10.1097/JTO.0b013e31817c73d6

Saunders, Y., Ross, J. R., Broadley, K. E., Edmonds, P. M., & Patel, S. (Writers). (2004). Systematic review of bisphosphonates for hypercalcaemia of malignancy.

Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., . . . Force, E. R. S. E. S. o. T. S. T. (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 35(3), 479-495. https://doi.org/10.1183/09031936.00063109

Schild, S. E., Bonner, J. A., Shanahan, T. G., Brooks, B. J., Marks, R. S., Geyer, S. M., . . . Jett, J. R. (2004). Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 59(4), 943-951.

Schild, S. E., Sio, T. T., Daniels, T. B., Chun, S. G., & Rades, D. (2017). Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. J Oncol Pract, 13(11), 732-738. https://doi.org/10.1200/JOP.2017.026765

Schindewolf, M., & Weitz, J. I. (2020). Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thromb Haemost, 120(1), 14-26. https://doi.org/10.1055/s-0039-3400302

Schmidt-Hansen, M., Baldwin, D. R., & Hasler, E. (2012). What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol, 7(5), 821-824. https://doi.org/10.1097/JTO.0b013e31824afc55

Schneider, B. J., Ismaila, N., Aerts, J., Chiles, C., Daly, M. E., Detterbeck, F. C., . . . Altorki, N. (2020). Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol, 38(7), 753-766. https://doi.org/10.1200/JCO.19.02748

Schneider, B. J., Saxena, A., & Downey, R. J. (2011). Surgery for early-stage small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1132-1139.

Schneider, J. (2006). Tumor markers in detection of lung cancer. Adv Clin Chem, 42, 1-41.

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., . . . Hellmann, M. D. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol, 30(5), 839-844. https://doi.org/10.1093/annonc/mdz077

Schoenmaekers, J. J. A. O., Dingemans, A. C., & Hendriks, L. E. L. (2018). Brain imaging in early stage non-small cell lung cancer: still a controversial topic? J Thorac Dis, 10(Suppl 18), S2168-S2171. https://doi.org/10.21037/jtd.2018.06.68

Schoser, B., Eymard, B., Datt, J., & Mantegazza, R. (2017). Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol, 264(9), 1854-1863. https://doi.org/10.1007/s00415-017-8541-9

Schreiber, D., Rineer, J., Weedon, J., Vongtama, D., Wortham, A., Kim, A., . . . Rotman, M. (2010). Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 116(5), 1350-1357. https://doi.org/10.1002/cncr.24853

Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998). Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer, 19(2), 141-151.

Sechi, E., & Zekeridou, A. (2021). Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. J Thorac Oncol, 16(3), 381-394. https://doi.org/10.1016/j.jtho.2020.11.005

Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., . . . Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 31(27), 3327-3334. https://doi.org/10.1200/JCO.2012.44.2806

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., . . . investigators, s. (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol, 17(2), 234-242. https://doi.org/10.1016/S1470-2045(15)00488-X

Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., . . . Engelman, J. A. (2014). Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370(13), 1189-1197. https://doi.org/10.1056/NEJMoa1311107

Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., . . . Jänne, P. A. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368(25), 2385-2394. https://doi.org/10.1056/NEJMoa1214886

Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., . . . Iafrate, A. J. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 371(21), 1963-1971. https://doi.org/10.1056/NEJMoa1406766

Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C. C., Soo, R. A., . . . Martini, J. F. (2019). Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol, 37(16), 1370-1379. https://doi.org/10.1200/JCO.18.02236

Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., . . . Ou, S. I. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(19)30655-2

Shaw, P., & Agarwal, R. (2004). Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev, (1).

Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., . . . Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18(10), 2095-2103.

Shirvani, S. M., Komaki, R., Heymach, J. V., Fossella, F. V., & Chang, J. Y. (2012). Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 82(1), e91-97. https://doi.org/10.1016/j.ijrobp.2010.12.072

Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., . . . Physicians, A. C. o. C. (2007). Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 178S-201S. https://doi.org/10.1378/chest.07-1360

Simon, G. R., Turrisi, A., & Physicians, A. C. o. C. (2007). Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 324S-339S. https://doi.org/10.1378/chest.07-1385

Simone, C. B. (2017). Thoracic Radiation Normal Tissue Injury. Semin Radiat Oncol, 27(4), 370-377. https://doi.org/10.1016/j.semradonc.2017.04.009

Skov, B. G., & Skov, T. (2017). Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol, 25(7), 453-459. https://doi.org/10.1097/PAI.0000000000000540

Skulberg, A. K., Mathisen, L. C., & Vaagbø, G. (2016). [Treatment of air embolisms]. Tidsskr Nor Laegeforen, 136(12-13), 1070. https://doi.org/10.4045/tidsskr.16.0455

Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., . . . Senan, S. (2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 385(9962), 36-42. https://doi.org/10.1016/S0140-6736(14)61085-0

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., . . . Group, I. S. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 378(24), 2288-2301. https://doi.org/10.1056/NEJMoa1716948

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., . . . Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 19(12), 1654-1667. https://doi.org/10.1016/S1470-2045(18)30649-1

Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., . . . Investigators, P. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 371(23), 2167-2177. https://doi.org/10.1056/NEJMoa1408440

Song, W. A., Zhou, N. K., Wang, W., Chu, X. Y., Liang, C. Y., Tian, X. D., . . . Dai, W. M. (2010). Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol, 5(4), 510-516. https://doi.org/10.1097/JTO.0b013e3181cd3345

Sonobe, M., Yamada, T., Sato, M., Menju, T., Aoyama, A., Sato, T., . . . Date, H. (2014). Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol, 21(8), 2546-2554. https://doi.org/10.1245/s10434-014-3630-9

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., . . . Investigators, F. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 378, 113-125. https://doi.org/10.1056/NEJMoa1713137

Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., . . . de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 389(10072), 917-929. https://doi.org/10.1016/S0140-6736(17)30123-X

Soria, J. C., Wu, Y. L., Nakagawa, K., Kim, S. W., Yang, J. J., Ahn, M. J., . . . Mok, T. S. (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol, 16(8), 990-998. https://doi.org/10.1016/S1470-2045(15)00121-7

Spigel, D., McLeod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., . . . Jotte, R. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol, 28, v460-v496.

Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., . . . Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol, 32(5), 631-641. https://doi.org/10.1016/j.annonc.2021.01.071

Spiro, S. G. (2012). Screening for lung cancer: we still need to know more. Thorax, 67(4), 283-285. https://doi.org/10.1136/thoraxjnl-2011-201541

Stahel, R. A., Weder, W., Lievens, Y., Felip, E., & Group, E. G. W. (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v126-128. https://doi.org/10.1093/annonc/mdq173

Stanic, S., Paulus, R., Timmerman, R. D., Michalski, J. M., Barriger, R. B., Bezjak, A., . . . Bradley, J. (2014). No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys, 88(5), 1092-1099. https://doi.org/10.1016/j.ijrobp.2013.12.050

Stovold, R., Blackhall, F., Meredith, S., Hou, J., Dive, C., & White, A. (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer, 76(3), 263-268. https://doi.org/10.1016/j.lungcan.2011.11.015

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., . . . Investigators, N.-T. (2017). Phase 3 Trial of. N Engl J Med, 376(2), 125-135. https://doi.org/10.1056/NEJMoa1607427

Strøm, H. H., Bremnes, R. M., Sundstrøm, S. H., Helbekkmo, N., Fløtten, O., & Aasebø, U. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer, 109(6), 1467-1475. https://doi.org/10.1038/bjc.2013.466

Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., . . . Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117(1), 54-63.

Suh, J. H. (2010). Stereotactic radiosurgery for the management of brain metastases. N Engl J Med, 362(12), 1119-1127. https://doi.org/10.1056/NEJMct0806951

Sun, J. M., Ahn, M. J., Ahn, J. S., Um, S. W., Kim, H., Kim, H. K., . . . Park, K. (2012). Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer, 77(2), 365-370. https://doi.org/10.1016/j.lungcan.2012.04.009

Sun, L., Davis, C. W., Hwang, W. T., Jeffries, S., Sulyok, L. F., Marmarelis, M. E., . . . Aggarwal, C. (2020). Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2020.10.017

Sundstrom, S., Bremnes, R., Brunsvig, P., Aasebo, U., Olbjorn, K., Fayers, P. M., & Kaasa, S. (2005). Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol, 75(2), 141-148.

Sundstrom, S., Bremnes, R., Aasebo, U., Aamdal, S., Hatlevoll, R., Brunsvig, P., . . . Kaasa, S. (2004). Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol, 22(5), 801-810.

Sundstrom, S., Bremnes, R. M., Kaasa, S., Aasebo, U., Hatlevoll, R., Dahle, R., . . . Aamdal, S. (2002). Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol, 20(24), 4665-4672.

Søgaard, R., Fischer, B. M., Mortensen, J., Højgaard, L., & Lassen, U. (2011). Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging, 38(5), 802-809. https://doi.org/10.1007/s00259-010-1703-y

Sørensen, M., Pijls-Johannesma, M., Felip, E., & Group, E. G. W. (2010). Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v120-125. https://doi.org/10.1093/annonc/mdq172

Sørensen, S., Helweg-Larsen, S., Mouridsen, H., & Hansen, H. H. (1994). Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer, 30A(1), 22-27.

Takamochi, K., Yoshida, J., Murakami, K., Niho, S., Ishii, G., Nishimura, M., . . . Nagai, K. (2005). Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer, 47(2), 235-242. https://doi.org/10.1016/j.lungcan.2004.08.004

Takenaka, D., Ohno, Y., Koyama, H., Nogami, M., Onishi, Y., Matsumoto, K., . . . Sugimura, K. (2010). Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol, 74(3), 458-464. https://doi.org/10.1016/j.ejrad.2009.03.007

Tan, B. B., Flaherty, K. R., Kazerooni, E. A., Iannettoni, M. D., & Physicians, A. C. o. C. (2003). The solitary pulmonary nodule. Chest, 123(1 Suppl), 89S-96S.

Tassinari, D., Scarpi, E., Sartori, S., Tamburini, E., Santelmo, C., Tombesi, P., & Lazzari-Agli, L. (2009). Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest, 135(6), 1596-1609.

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., . . . Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 363(8), 733-742. https://doi.org/10.1056/NEJMoa1000678

Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., . . . Tomii, K. (2017). Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol, 12(12), 1798-1805. https://doi.org/10.1016/j.jtho.2017.08.022

Thatcher, N., Nicolson, M., Groves, R. W., Steele, J., Eaby, B., Dunlop, J., . . . Ukachukwu, I. (2009). Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist, 14(8), 840-847.

Travis, W. D. (2014). Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin, 24(3), 257-266. https://doi.org/10.1016/j.thorsurg.2014.04.001

Travis, W. D., Asamura, H., Bankier, A. A., Beasley, M. B., Detterbeck, F., Flieder, D. B., . . . Members, I. A. f. t. S. o. L. C. S. a. P. F. C. a. A. B. (2016). The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol, 11(8), 1204-1223. https://doi.org/10.1016/j.jtho.2016.03.025

Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer.

Travis, W. D., Brambilla, E., Rami-Porta, R., Vallières, E., Tsuboi, M., Rusch, V., . . . Committee, I. S. (2008). Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol, 3(12), 1384-1390. https://doi.org/10.1097/JTO.0b013e31818e0d9f

Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J., . . . trialists, M. (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol, 12(8), 763-772. https://doi.org/10.1016/S1470-2045(11)70149-8

Truong, M. T., Ko, J. P., Rossi, S. E., Rossi, I., Viswanathan, C., Bruzzi, J. F., . . . Erasmus, J. J. (2014). Update in the evaluation of the solitary pulmonary nodule. Radiographics, 34(6), 1658-1679. https://doi.org/10.1148/rg.346130092

Truong, M. T., Viswanathan, C., Godoy, M. B., Carter, B. W., & Marom, E. M. (2013). Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations. Semin Roentgenol, 48(4), 323-334. https://doi.org/10.1053/j.ro.2013.03.017

Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., . . . Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006

Tsuya, A., Kurata, T., Tamura, K., & Fukuoka, M. (2007). Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 57(2), 229-232.

Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., . . . Johnson, D. H. (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340(4), 265-271.

Vallieres, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., . . . Goldstraw, P. (2009). The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 4(9), 1049-1059.

van Loon, J., De Ruysscher, D., Wanders, R., Boersma, L., Simons, J., Oellers, M., . . . Lambin, P. (2010). Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys, 77(2), 329-336. https://doi.org/10.1016/j.ijrobp.2009.04.075

van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., . . . Giaccone, G. (2005). Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 23(28), 6881-6889.

van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., . . . Group, E. O. f. R. a. T. o. C.-L. C. (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 99(6), 442-450. https://doi.org/10.1093/jnci/djk093

van Thiel, E. R., Surmont, V. F., & van Meerbeeck, J. P. (2011). Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 11(4), 551-560. https://doi.org/10.1586/era.10.169

Vergnon, J. M., Huber, R. M., & Moghissi, K. (2006). Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J, 28(1), 200-218.

Veronesi, G., Morandi, U., Alloisio, M., Terzi, A., Cardillo, G., Filosso, P., . . . Spaggiari, L. (2006). Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer, 53(1), 111-115. https://doi.org/10.1016/j.lungcan.2006.03.007

Veronesi, G., Novellis, P., Voulaz, E., & Alloisio, M. (2016). Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer, 101, 28-34. https://doi.org/10.1016/j.lungcan.2016.09.004

Vidal, J., Clavé, S., de Muga, S., González, I., Pijuan, L., Gimeno, J., . . . Arriola, E. (2014). Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J Thorac Oncol, 9(12), 1816-1820. https://doi.org/10.1097/JTO.0000000000000361

Vilmann, P., Clementsen, P. F., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J. M., . . . Annema, J. T. (2015). Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy, 47(6), c1. https://doi.org/10.1055/s-0034-1392453

Vogelius, I. R., & Bentzen, S. M. (2012). A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol, 51(8), 975-983. https://doi.org/10.3109/0284186X.2012.718093

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., . . . Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21(14), 2636-2644.

von Meyenfeldt, E. M., Prevoo, W., Peyrot, D., Lai A Fat, N., Burgers, S. J., Wouters, M. W., & Klomp, H. M. (2011). Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 117(16), 3781-3787. https://doi.org/10.1002/cncr.25958

von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., . . . Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 19(6), 1743-1749.

von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., . . . Gralla, R. (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17(2), 658-667.

von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrom, S., Gilleryd, M., . . . Sorenson, S. (2006). Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer, 95(8), 966-973. https://doi.org/6603383 [pii] 10.1038/sj.bjc.6603383

Wahidi, M. M., Govert, J. A., Goudar, R. K., Gould, M. K., McCrory, D. C., & Physicians, A. C. o. C. (2007). Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 94S-107S. https://doi.org/10.1378/chest.07-1352

Waite, K., & Gilligan, D. (2007). The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol), 19(3), 182-187. https://doi.org/S0936-6555(06)00435-3 [pii] 10.1016/j.clon.2006.12.006

Waldeland, E., Brustugun, O. T., Ramberg, C., & Helland, Å. (2012). [Stereotactic irradiation in spinal metastases]. Tidsskr Nor Laegeforen, 132(22), 2478-2479. https://doi.org/10.4045/tidsskr.12.1108

Walji, N., Chan, A. K., & Peake, D. R. (2008). Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J, 84(994), 418-427.

Wang, E. H., Corso, C. D., Rutter, C. E., Park, H. S., Chen, A. B., Kim, A. W., . . . Yu, J. B. (2015). Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol, 33(25), 2727-2734. https://doi.org/10.1200/JCO.2015.61.1517

Warren, G. W., Alberg, A. J., Kraft, A. S., & Cummings, K. M. (2014). The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer, 120(13), 1914-1916. https://doi.org/10.1002/cncr.28695

Watanabe, S. M., Nekolaichuk, C. L., & Beaumont, C. (2012). The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology, 21(9), 977-985. https://doi.org/10.1002/pon.1996

Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., . . . Research, S. G. f. C. C. (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol, 18(7), 1196-1202. https://doi.org/10.1093/annonc/mdm093

Wei, M. L., Kang, D., Gu, L., Qiu, M., Zhengyin, L., & Mu, Y. (2013). Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database Syst Rev, 8, CD008588. https://doi.org/10.1002/14651858.CD008588.pub2

Weichselbaum, R. R., & Hellman, S. (2011). Oligometastases revisited. Nat Rev Clin Oncol, 8(6), 378-382. https://doi.org/10.1038/nrclinonc.2011.44

WHO Classification of Tumours 5th ed.  Thoracic tumours. (2021). (Vol. 5). International Agency for Research on Cancer,  Lyon (France): WHO.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer, 104, 182-187. https://doi.org/10.1016/j.ejca.2018.09.012

Wilson, J. M., & Jungner, Y. G. (1968). [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam, 65(4), 281-393.

Wilson, L. D., Detterbeck, F. C., & Yahalom, J. (2007). Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med, 356(18), 1862-1869.

Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., . . . Shepherd, F. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 352(25), 2589-2597.

Wirth, L. J., Carter, M. R., Jänne, P. A., & Johnson, B. E. (2004). Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer, 44(2), 213-220. https://doi.org/10.1016/j.lungcan.2003.11.016

Wolfson, A. H., Bae, K., Komaki, R., Meyers, C., Movsas, B., Le Pechoux, C., . . . Choy, H. (2011). Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys, 81(1), 77-84. https://doi.org/10.1016/j.ijrobp.2010.05.013

Wolin, E. M. (2017). Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Chest, 151(5), 1141-1146. https://doi.org/10.1016/j.chest.2016.06.018

Wu, Y. L., Ahn, M. J., Garassino, M. C., Han, J. Y., Katakami, N., Kim, H. R., . . . Mok, T. S. K. (2018). CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol, 36(26), 2702-2709. https://doi.org/10.1200/JCO.2018.77.9363

Wu, Y. L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Mok, T. S. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol, 18(11), 1454-1466. https://doi.org/10.1016/S1470-2045(17)30608-3

Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., . . . Investigators, A. (2020). Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med, 383(18), 1711-1723. https://doi.org/10.1056/NEJMoa2027071

Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., . . . Geater, S. L. (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 15(2), 213-222. https://doi.org/10.1016/S1470-2045(13)70604-1

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Jokura, H. (2014). Stereotactic radiosurgery for patients with brain metastases - authors' reply. Lancet Oncol, 15(7), e248. https://doi.org/10.1016/S1470-2045(14)70221-9

Yamazaki, S., Sekine, I., Matsuno, Y., Takei, H., Yamamoto, N., Kunitoh, H., . . . Saijo, N. (2005). Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer, 49(2), 217-223. https://doi.org/10.1016/j.lungcan.2005.01.008

Yang, S. Y., Kim, D. G., Lee, S. H., Chung, H. T., Paek, S. H., Hyun Kim, J., . . . Han, D. H. (2008). Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer, 112(8), 1780-1786. https://doi.org/10.1002/cncr.23357

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., . . . RAD001 in Advanced Neuroendocrine Tumours, F. u. T. R.-S. G. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-977. https://doi.org/10.1016/S0140-6736(15)00817-X

Yokoba, M., Ichikawa, T., Harada, S., Naito, M., Sato, Y., & Katagiri, M. (2018). Postoperative pulmonary function changes according to the resected lobe: a 1-year follow-up study of lobectomized patients. J Thorac Dis, 10(12), 6891-6902. https://doi.org/10.21037/jtd.2018.11.108

Yu, J. B., Decker, R. H., Detterbeck, F. C., & Wilson, L. D. (2010). Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 5(2), 215-219. https://doi.org/10.1097/JTO.0b013e3181cd3208

Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W., Komaki, R., Wagner, H., . . . Johnson, D. H. (2000). Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer, 89(9), 1953-1960.

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., . . . (IFCT), F. C. T. I. (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 387(10026), 1405-1414. https://doi.org/10.1016/S0140-6736(15)01238-6

Zhao, C., & Rajan, A. (2019). Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum, 3. https://doi.org/10.21037/med.2019.08.02

Zhu, H., Guo, H., Shi, F., Zhu, K., Luo, J., Liu, X., . . . Yu, J. (2014). Prophylactic cranial irradiation improved the overall survival of patients with surgically        resected small cell lung cancer, but not for stage I disease. Lung Cancer, 86(3),  334-338. https://doi.org/10.1016/j.lungcan.2014.09.019

Sist faglig oppdatert: 23. desember 2021